"It tested a novel vaccine, based on Penn’s groundbreaking mRNA research, that trains the patient’s immune system to find and kill cancer cells.That technology has become the first mRNA cancer vaccine to succeed in a late-stage clinical trial."
@kimdefalco.bsky.social